Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting

Michael Scott Kook, Susan Simonyi, Yong Ho Sohn, Chan Yun Kim, Ki Ho Park

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To evaluate the occurrence of hyperemia with, and efficacy of, bimatoprost 0.01 % for patients in Korea previously treated for open-angle glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT). Methods: In this multicenter, observational study (Asia Pacific Patterns from Early Access of Lumigan 0.01 % in Korea; APPEAL Korea), patients with unachieved target intraocular pressure (IOP) despite previous treatment received bimatoprost 0.01 % daily for 12 weeks. The primary endpoint was incidence of hyperemia and its severity, graded using the standard 5-point photographic scale and grouped as “none to mild” and “moderate to severe”. Hyperemia shifts were reported. IOP and adverse events (AEs) were recorded. Results: Of 800 patients (intent-to-treat/safety population), 248 were switched from previous treatment to bimatoprost 0.01 % monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 were unchanged (84.8, 89.8 %), improved (4.4, 4.8 %), or worsened (10.8, 5.4 %), respectively. The shift was significant at week 6 (P < 0.0001). Hyperemia did not worsen significantly in patients previously receiving a prostaglandin analog or prostamide (PGA/PSD). Baseline mean IOP ± SD was 17.0 ± 5.7 mmHg, decreasing to 14.6 ± 3.8 mmHg (P < 0.0001) after 6 weeks, and to 14.7 ± 3.6 mmHg (P < 0.0001) after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 %) to bimatoprost 0.01 % experienced significant IOP reductions from baseline. Treatment-related ocular AEs were reported by 37 patients, the most common being hyperemia (7.3 %). Conclusions: This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 % for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment.

Original languageEnglish
Pages (from-to)325-334
Number of pages10
JournalJapanese Journal of Ophthalmology
Volume59
Issue number5
DOIs
Publication statusPublished - 2015 Sep 14

Fingerprint

Ocular Hypertension
Open Angle Glaucoma
Hyperemia
Korea
Intraocular Pressure
Low Tension Glaucoma
Prostaglandins A
Synthetic Prostaglandins
Therapeutics
Bimatoprost
Multicenter Studies
Observational Studies
Safety
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{18c82b2379b94b7daead9b83467752d9,
title = "Bimatoprost 0.01 {\%} for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting",
abstract = "Purpose: To evaluate the occurrence of hyperemia with, and efficacy of, bimatoprost 0.01 {\%} for patients in Korea previously treated for open-angle glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT). Methods: In this multicenter, observational study (Asia Pacific Patterns from Early Access of Lumigan 0.01 {\%} in Korea; APPEAL Korea), patients with unachieved target intraocular pressure (IOP) despite previous treatment received bimatoprost 0.01 {\%} daily for 12 weeks. The primary endpoint was incidence of hyperemia and its severity, graded using the standard 5-point photographic scale and grouped as “none to mild” and “moderate to severe”. Hyperemia shifts were reported. IOP and adverse events (AEs) were recorded. Results: Of 800 patients (intent-to-treat/safety population), 248 were switched from previous treatment to bimatoprost 0.01 {\%} monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 were unchanged (84.8, 89.8 {\%}), improved (4.4, 4.8 {\%}), or worsened (10.8, 5.4 {\%}), respectively. The shift was significant at week 6 (P < 0.0001). Hyperemia did not worsen significantly in patients previously receiving a prostaglandin analog or prostamide (PGA/PSD). Baseline mean IOP ± SD was 17.0 ± 5.7 mmHg, decreasing to 14.6 ± 3.8 mmHg (P < 0.0001) after 6 weeks, and to 14.7 ± 3.6 mmHg (P < 0.0001) after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 {\%}) to bimatoprost 0.01 {\%} experienced significant IOP reductions from baseline. Treatment-related ocular AEs were reported by 37 patients, the most common being hyperemia (7.3 {\%}). Conclusions: This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 {\%} for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment.",
author = "Kook, {Michael Scott} and Susan Simonyi and Sohn, {Yong Ho} and Kim, {Chan Yun} and Park, {Ki Ho}",
year = "2015",
month = "9",
day = "14",
doi = "10.1007/s10384-015-0392-2",
language = "English",
volume = "59",
pages = "325--334",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "5",

}

Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting. / Kook, Michael Scott; Simonyi, Susan; Sohn, Yong Ho; Kim, Chan Yun; Park, Ki Ho.

In: Japanese Journal of Ophthalmology, Vol. 59, No. 5, 14.09.2015, p. 325-334.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting

AU - Kook, Michael Scott

AU - Simonyi, Susan

AU - Sohn, Yong Ho

AU - Kim, Chan Yun

AU - Park, Ki Ho

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Purpose: To evaluate the occurrence of hyperemia with, and efficacy of, bimatoprost 0.01 % for patients in Korea previously treated for open-angle glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT). Methods: In this multicenter, observational study (Asia Pacific Patterns from Early Access of Lumigan 0.01 % in Korea; APPEAL Korea), patients with unachieved target intraocular pressure (IOP) despite previous treatment received bimatoprost 0.01 % daily for 12 weeks. The primary endpoint was incidence of hyperemia and its severity, graded using the standard 5-point photographic scale and grouped as “none to mild” and “moderate to severe”. Hyperemia shifts were reported. IOP and adverse events (AEs) were recorded. Results: Of 800 patients (intent-to-treat/safety population), 248 were switched from previous treatment to bimatoprost 0.01 % monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 were unchanged (84.8, 89.8 %), improved (4.4, 4.8 %), or worsened (10.8, 5.4 %), respectively. The shift was significant at week 6 (P < 0.0001). Hyperemia did not worsen significantly in patients previously receiving a prostaglandin analog or prostamide (PGA/PSD). Baseline mean IOP ± SD was 17.0 ± 5.7 mmHg, decreasing to 14.6 ± 3.8 mmHg (P < 0.0001) after 6 weeks, and to 14.7 ± 3.6 mmHg (P < 0.0001) after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 %) to bimatoprost 0.01 % experienced significant IOP reductions from baseline. Treatment-related ocular AEs were reported by 37 patients, the most common being hyperemia (7.3 %). Conclusions: This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 % for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment.

AB - Purpose: To evaluate the occurrence of hyperemia with, and efficacy of, bimatoprost 0.01 % for patients in Korea previously treated for open-angle glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT). Methods: In this multicenter, observational study (Asia Pacific Patterns from Early Access of Lumigan 0.01 % in Korea; APPEAL Korea), patients with unachieved target intraocular pressure (IOP) despite previous treatment received bimatoprost 0.01 % daily for 12 weeks. The primary endpoint was incidence of hyperemia and its severity, graded using the standard 5-point photographic scale and grouped as “none to mild” and “moderate to severe”. Hyperemia shifts were reported. IOP and adverse events (AEs) were recorded. Results: Of 800 patients (intent-to-treat/safety population), 248 were switched from previous treatment to bimatoprost 0.01 % monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 were unchanged (84.8, 89.8 %), improved (4.4, 4.8 %), or worsened (10.8, 5.4 %), respectively. The shift was significant at week 6 (P < 0.0001). Hyperemia did not worsen significantly in patients previously receiving a prostaglandin analog or prostamide (PGA/PSD). Baseline mean IOP ± SD was 17.0 ± 5.7 mmHg, decreasing to 14.6 ± 3.8 mmHg (P < 0.0001) after 6 weeks, and to 14.7 ± 3.6 mmHg (P < 0.0001) after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 %) to bimatoprost 0.01 % experienced significant IOP reductions from baseline. Treatment-related ocular AEs were reported by 37 patients, the most common being hyperemia (7.3 %). Conclusions: This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 % for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment.

UR - http://www.scopus.com/inward/record.url?scp=84941426846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941426846&partnerID=8YFLogxK

U2 - 10.1007/s10384-015-0392-2

DO - 10.1007/s10384-015-0392-2

M3 - Article

C2 - 26202440

AN - SCOPUS:84941426846

VL - 59

SP - 325

EP - 334

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 5

ER -